Table 3.
COVID-19 presentation of COVID-19 positive cancer patients.
| Total (n = 156) | WHO COVID grade | |||||
|---|---|---|---|---|---|---|
| Mild/moderate (n = 128) | Severe (n = 28) | |||||
| n | % | n | % | n | % | |
| Symptoms | ||||||
| Cough | 72 | 46.20 | 57 | 44.50 | 15 | 53.60 |
| Fever | 81 | 51.90 | 59 | 46.10 | 22 | 78.60 |
| Dyspnoea | 55 | 35.30 | 41 | 32.00 | 14 | 50.00 |
| Gastro-intestinal symptoms | 25 | 16.00 | 13 | 10.20 | 12 | 42.90 |
| Time between first symptom and diagnosis | ||||||
| <7 days | 90 | 57.70 | 71 | 55.50 | 19 | 67.90 |
| 7–14 days | 27 | 17.30 | 22 | 17.20 | 5 | 17.90 |
| >14 days | 14 | 9.00 | 11 | 8.60 | 3 | 10.70 |
| Missing | 25 | 16.00 | 24 | 18.80 | 1 | 3.60 |
| Care setting | ||||||
| Outpatient | 36 | 23.10 | 36 | 28.10 | 0 | 0.00 |
| Inpatient | 105 | 67.30 | 90 | 70.30 | 15 | 53.60 |
| ITU | 13 | 8.30 | 0 | 0.00 | 13 | 46.40 |
| Missing | 2 | 1.30 | 2 | 1.60 | 0 | 0.00 |
| Laboratory values* | ||||||
| Ferritin (μg/L) | ||||||
| T1 (80–793) | 18 | 11.50 | 14 | 10.90 | 4 | 14.30 |
| T2 (891–1,442) | 18 | 11.50 | 13 | 10.20 | 5 | 17.90 |
| T3 (1,596–5,958) | 17 | 10.90 | 10 | 7.80 | 7 | 25.00 |
| Missing | 103 | 66.00 | 91 | 71.10 | 12 | 42.90 |
| CRP (mg/L) | ||||||
| T1 (3–41) | 44 | 28.20 | 38 | 29.70 | 6 | 21.40 |
| T2 (42–117) | 39 | 25.00 | 30 | 23.40 | 9 | 32.10 |
| T3 (126–508) | 41 | 26.30 | 28 | 21.90 | 13 | 46.40 |
| Missing | 32 | 20.50 | 32 | 25.00 | 0 | 0.00 |
| Lymphocytes (×109) | ||||||
| ≤0.5 | 39 | 25.00 | 27 | 21.10 | 12 | 42.90 |
| 0.6–0.8 | 38 | 24.40 | 30 | 23.40 | 8 | 28.60 |
| 0.9–1.2 | 27 | 17.30 | 25 | 19.50 | 2 | 7.10 |
| >1.2 | 27 | 17.30 | 21 | 16.40 | 6 | 21.40 |
| Missing | 25 | 16.00 | 25 | 19.50 | 0 | 0.00 |
| Albumin (g/L) | ||||||
| T1 (20–32) | 39 | 25.00 | 28 | 21.90 | 11 | 39.30 |
| T2 (33–38) | 43 | 27.60 | 32 | 25.00 | 11 | 39.30 |
| T3 (39–57) | 34 | 21.80 | 32 | 25.00 | 2 | 7.10 |
| Missing | 40 | 25.60 | 36 | 28.10 | 4 | 14.30 |
*
Distribution shown in tertiles (T).